PDF file: The Use of Partial Fatty
Acid Oxidation Inhibitors for Metabolic Therapy of Angina
Pectoris and Heart Failure
Functional Genomics of the
Pressure Overloaded Cardiomyocyte. Is Heart Failure a
Target for Etomoxir?
Acute Heart Failure – Basic
Pathomechanism and New Drug Targets.
of EPA and DHA in dilative heart failure - a rational
teatment target for omega-3 fatty acids:
Rupp TP, Alter P, Maisch B. Can J Physiol Pharmacol.
2012;90:55-73 Open Access
involved in the differential reduction of omega-3 and
omega-6 highly unsaturated fatty acids by structural heart
disease resulting in "HUFA deficiency".
omega-3 fatty acids in the blood and risk stratification
by the EPA+DHA level
Rupp TP, Wagner D, Alter P, Maisch B. Microdetermination of
fatty acids by gas chromatography and cardiovascular risk
stratification by the "EPA+DHA level". Herz 2006;31Suppl
stratification by the EPA+DHA level and the
EPA/arachidonic acid (EPA/AA) ratio
H, Wagner D, Rupp T, Schulte L, Maisch B. Risk
stratification by the "EPA+DHA Level" and the "EPA/AA
Ratio". Focus on anti-inflammatory and antiarrythmogenic
effects of long-chain omega-3 fatty acids. Herz 2004;
November 12, 2013